#Shutdown thrusts Gossamer Bio onto a rarely used path for fixed-price IPO – via @Endpts News

From day 1 Gos­samer has al­ways been a biotech in a hurry. And they’re not about to let a lit­tle thing like a gov­ern­ment shut­down stymy their plans for an IPO.

Source: Shutdown thrusts Gossamer Bio onto a rarely used path for fixed-price IPO – Endpoints News